1. Home
  2. LCTX vs CMRC Comparison

LCTX vs CMRC Comparison

Compare LCTX & CMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

393.9M

Sector

Health Care

ML Signal

HOLD

Logo Commerce.com Inc. Series 1 Common Stock

CMRC

Commerce.com Inc. Series 1 Common Stock

N/A

Current Price

$4.33

Market Cap

399.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LCTX
CMRC
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
393.9M
399.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LCTX
CMRC
Price
$1.68
$4.33
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$4.25
$7.50
AVG Volume (30 Days)
1.3M
645.0K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,816,000.00
$339,860,000.00
Revenue This Year
$5.24
$5.15
Revenue Next Year
$126.78
$4.15
P/E Ratio
N/A
N/A
Revenue Growth
24.05
2.97
52 Week Low
$0.37
$4.14
52 Week High
$2.09
$7.69

Technical Indicators

Market Signals
Indicator
LCTX
CMRC
Relative Strength Index (RSI) 46.00 36.97
Support Level $1.69 $4.46
Resistance Level $1.79 $4.61
Average True Range (ATR) 0.08 0.15
MACD -0.00 -0.02
Stochastic Oscillator 43.75 2.88

Price Performance

Historical Comparison
LCTX
CMRC

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About CMRC Commerce.com Inc. Series 1 Common Stock

Commerce.com Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of its revenue is generated from Americas-U.S.

Share on Social Networks: